Search - tctmd.com

Displaying 221 - 240 of 786

Sort: Relevancy | Date

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

Presenter: Stephen G. Ellis, John A. Ormiston, Pieter C. Smits

October 11, 2015

Presentation TCT 2015

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Presenter: Stephen G. Ellis, John A. Ormiston, Evald H. Christiansen

October 11, 2015

Presentation TCT 2015

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Presenter: Stephen G. Ellis, John A. Ormiston, Dean J. Kereiakes

October 11, 2015

Presentation TCT 2015

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Presenter: Stephen G. Ellis, John A. Ormiston, Philip M. Urban

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Industry News

Boston Scientific Announces Scheduled Presentations At TCT 2015

October 08, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Industry News

STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease

September 29, 2015

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

News Industry News

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

September 01, 2015

Advertisement

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

What Have We Learned From All-Comers Head-to-Head DES Trials II? The COMPARE Trials

What Have We Learned From All-Comers Head-to-Head DES Trials I? The SORT OUT Trial

Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update

Update on Biolimus-Eluting Stent Platforms: BioMatrix and Nobori Program Update

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Boston Scientific Announces Scheduled Presentations At TCT 2015

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content